SURPASS-PEDS: Tirzepatide Improved HbA1c in Youth-Onset Type 2 Diabetes
In SURPASS-PEDS, weekly tirzepatide lowered HbA1c by 2.28 points versus placebo at 30 weeks and also reduced BMI in youth-onset type 2 diabetes.
Tirzepatide
SURMOUNT-1: Tirzepatide Achieves up to 20.9% Weight Loss in Obesity — Entering Surgical Territory
SURMOUNT-1 demonstrated that tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent mean weight reductions of 15.0–20.9% in adults with obesity without type 2 diabetes, with 57% of participants at the 15 mg dose losing 20% or more of body weight, setting a new pharmacological efficacy benchmark comparable in magnitude to bariatric surgery outcomes.
How do Tirzepatide and Dulaglutide compare for cardiovascular outcomes in Type 2 Diabetes?
The SURPASS-CVOT trial finds tirzepatide noninferior but not superior to dulaglutide for major cardiovascular events in type 2 diabetes, confirming both incretin therapies are cardioprotective. PICO summary and commentary.
Does Tirzepatide Improve Quality of Life More Than Semaglutide in Obesity?
A SURMOUNT-5 analysis finds tirzepatide and semaglutide improve physical quality of life in obesity, with neither improving mental-health scores. PICO summary and expert commentary.
Tirzepatide Preserves Glucagon Response to Hypoglycemia But Blunts Symptom Awareness: Clamp Study
A clamp study finds tirzepatide preserves the glucagon defence against hypoglycaemia but delays cortisol/noradrenaline and lowers symptom scores, while awareness is unchanged. PICO summary and commentary.
Tirzepatide Benefits in Obese HFpEF Consistent Regardless of Diabetes Status: SUMMIT Subanalysis
A prespecified SUMMIT analysis finds tirzepatide reduces heart-failure events in obese HFpEF regardless of diabetes status, despite less weight loss with diabetes. PICO summary and commentary.
Does Tirzepatide Improve Insulin Function in People With Obesity?
A SURMOUNT-1 analysis finds tirzepatide improves insulin sensitivity (mostly via weight loss) and beta-cell function (mostly drug-driven) in obesity without diabetes. PICO summary and commentary.
Does Early Weight Loss Predict Long-Term Results with Tirzepatide?
A SURMOUNT-1 analysis finds 90% of early non-responders to tirzepatide still reached 5% weight loss by week 72, supporting extending treatment. PICO summary and commentary.